Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 871609, 17 pages
http://dx.doi.org/10.1155/2014/871609
Review Article

PET Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments

1Department of Nuclear Medicine, Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria
2Molecular Imaging and Radiochemistry, Department of Nuclear Medicine, Friedrich-Alexander University, Schwabachanlage 6, 91054 Erlangen, Germany

Received 25 March 2014; Accepted 29 April 2014; Published 11 June 2014

Academic Editor: Patrick Riss

Copyright © 2014 Roland Haubner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Margadant, H. N. Monsuur, J. C. Norman, and A. Sonnenberg, “Mechanisms of integrin activation and trafficking,” Current Opinion in Cell Biology, vol. 23, no. 5, pp. 607–614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Welti, S. Loges, S. Dimmeler, and P. Carmeliet, “Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer,” The Journal of Clinical Investigation, vol. 123, no. 8, pp. 3190–3200, 2013. View at Publisher · View at Google Scholar
  3. M. Petrillo, G. Scambia, and G. Ferrandina, “Novel targets for VEGF-independent anti-angiogenic drugs,” Expert Opinion on Investigational Drugs, vol. 21, no. 4, pp. 451–472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Seystahl and M. Weller, “Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?” Expert Opinion on Investigational Drugs, vol. 21, no. 5, pp. 605–617, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Garmy-Susini and J. A. Varner, “Roles of integrins in tumor angiogenesis and lymphangiogenesis,” Lymphatic Research and Biology, vol. 6, no. 3-4, pp. 155–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Haubner, A. J. Beer, H. Wang, and X. Chen, “Positron emission tomography tracers for imaging angiogenesis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, supplement 1, pp. S86–S103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. C. Brooks, R. A. Clark, and D. A. Cheresh, “Requirement of vascular integrin alpha v beta 3 for angiogenesis,” Science, vol. 264, no. 5158, pp. 569–571, 1994. View at Google Scholar · View at Scopus
  8. F. C. Gaertner, H. Kessler, H. J. Wester, M. Schwaiger, and A. J. Beer, “Radiolabelled RGD peptides for imaging and therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, supplement 1, pp. 126–138, 2012. View at Google Scholar
  9. G. H. Mahabeleshwar, W. Feng, D. R. Phillips, and T. V. Byzova, “Integrin signaling is critical for pathological angiogenesis,” The Journal of Experimental Medicine, vol. 203, no. 11, pp. 2495–2507, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. K. L. Goh, J. T. Yang, and R. O. Hynes, “Mesodermal defects and cranial neural crest apoptosis in α5 integrin-null embryos,” Development, vol. 124, no. 21, pp. 4309–4319, 1997. View at Google Scholar
  11. S. Kim, K. Bell, S. A. Mousa, and J. A. Varner, “Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin,” The American Journal of Pathology, vol. 156, no. 4, pp. 1345–1362, 2000. View at Google Scholar · View at Scopus
  12. N. J. Boudreau and J. A. Varner, “The homeobox transcription factor hox D3 promotes integrin α5β1 expression and function during angiogenesis,” The Journal of Biological Chemistry, vol. 279, no. 6, pp. 4862–4868, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Bandyopadhyay and S. Raghavan, “Defining the role of integrin αvβ6 in cancer,” Current Drug Targets, vol. 10, no. 7, pp. 645–652, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Breuss, J. Gallo, H. M. DeLisser et al., “Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling,” Journal of Cell Science, vol. 108, no. 6, pp. 2241–2251, 1995. View at Google Scholar · View at Scopus
  15. R. A. Clark, G. S. Ashcroft, M.-J. Spencer, H. Larjava, and M. W. Ferguson, “Re-epithelialization of normal human excisional wounds is associated with a switch from αvβ5 to αvβ6 integrins,” British Journal of Dermatology, vol. 135, no. 1, pp. 46–51, 1996. View at Google Scholar
  16. R. C. Bates, “Colorectal cancer progression: integrin αvβ6 and the epithelial-mesenchymal transition (EMT),” Cell Cycle, vol. 4, no. 10, pp. 1350–1352, 2005. View at Google Scholar · View at Scopus
  17. R. Haubner, W. A. Weber, A. J. Beer et al., “Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD,” PLoS Medicine, vol. 2, no. 3, article e70, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. Kenny, R. C. Coombes, I. Oulie et al., “Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients,” The Journal of Nuclear Medicine, vol. 49, no. 6, pp. 879–886, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Wan, N. Guo, D. Pan et al., “First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination,” The Journal of Nuclear Medicine, vol. 54, no. 5, pp. 691–698, 2013. View at Publisher · View at Google Scholar
  20. J. Notni, K. Pohle, and H.-J. Wester, “Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of 68Ga-TRAP(RGD)3,” Nuclear Medicine and Biology, vol. 40, no. 1, pp. 33–41, 2013. View at Publisher · View at Google Scholar
  21. Z. Liu, Y. Li, J. Lozada et al., “Kit-like 18F-labeling of RGD-19F-Arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging,” Nuclear Medicine and Biology, vol. 40, no. 6, pp. 841–849, 2013. View at Google Scholar
  22. S. Neubauer, F. Rechenmacher, A. J. Beer et al., “Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3,” Angewandte Chemie, vol. 52, no. 44, pp. 11656–11659, 2013. View at Publisher · View at Google Scholar
  23. S. H. Hausner, D. DiCara, J. Marik, J. F. Marshall, and J. L. Sutcliffe, “Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin αvβ6 expression with positron emission tomography,” Cancer Research, vol. 67, no. 16, pp. 7833–7840, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. B. J. Hackel, R. H. Kimura, Z. Miao et al., “18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin αvβ6,” The Journal of Nuclear Medicine, vol. 54, no. 7, pp. 1101–1105, 2013. View at Publisher · View at Google Scholar
  25. L. Auzzas, F. Zanardi, L. Battistini et al., “Targeting αvβ3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides,” Current Medicinal Chemistry, vol. 17, no. 13, pp. 1255–1299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Cai and P. S. Conti, “RGD-based PET tracers for imaging receptor integrin αvβ3 expression,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 56, no. 5, pp. 264–279, 2013. View at Publisher · View at Google Scholar
  27. M. Schottelius, B. Laufer, H. Kessler, and H.-J. Wester, “Ligands for mapping αvβ3-integrin expression in vivo,” Accounts of Chemical Research, vol. 42, no. 7, pp. 969–980, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Haubner, B. Kuhnast, C. Mang et al., “[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates,” Bioconjugate Chemistry, vol. 15, no. 1, pp. 61–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Glaser, M. Solbakken, D. R. Turton et al., “Methods for 18F-labeling of RGD peptides: comparison of aminooxy [18F]fluorobenzaldehyde condensation with “click labeling” using 2-[18F]fluoroethylazide, and S-alkylation with [18F] fluoropropanethiol,” Amino Acids, vol. 37, no. 4, pp. 717–724, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Mirfeizi, J. Walsh, H. Kolb et al., “Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin αvβ3 expression in vivo,” Nuclear Medicine and Biology, vol. 40, no. 5, pp. 710–716, 2013. View at Publisher · View at Google Scholar
  31. Z.-B. Li, Z. Wu, K. Chen, F. T. Chin, and X. Chen, “Click chemistry for 18F-labeling of RGD peptides and microPET imaging of tumor integrin αvβ3 expression,” Bioconjugate Chemistry, vol. 18, no. 6, pp. 1987–1994, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Maschauer, R. Haubner, T. Kuwert, and O. Prante, “18F-Glyco-RGD peptides for PET imaging of integrin expression: efficient radiosynthesis by click chemistry and modulation of biodistribution by glycosylation,” Molecular Pharmaceutics, vol. 11, no. 2, pp. 505–515, 2014. View at Publisher · View at Google Scholar
  33. E. Schirrmacher, B. Wängler, M. Cypryk et al., “Synthesis of p-(Di-tert-butyl[18F]fluorosilyl)benzaldehyde ([18F]SiFA-A) with high specific activity by isotopic exchange: a convenient labeling synthon for the 18F-labeling of N-amino-oxy derivatized peptides,” Bioconjugate Chemistry, vol. 18, no. 6, pp. 2085–2089, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. M. Jeong, M. K. Hong, Y. S. Chang et al., “Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1, 4,7-triacetic acid and feasibility studies in mice,” The Journal of Nuclear Medicine, vol. 49, no. 5, pp. 830–836, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Decristoforo, I. H. Gonzalez, J. Carlsen et al., “68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 8, pp. 1507–1515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. P. A. Knetsch, M. Petrik, C. M. Griessinger et al., “[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 7, pp. 1303–1312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Šimeček, J. Notni, T. G. Kapp, H. Kessler, and H.-J. Wester, “Benefits of NOPO as chelator in Gallium-68 peptides, exemplified by preclinical characterization of 68Ga-NOPO-c(RGDfK),” Molecular Pharmaceutics, vol. 11, no. 5, pp. 1687–1695, 2014. View at Google Scholar
  38. E. Boros, C. L. Ferreira, D. T. Yapp et al., “RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga,” Nuclear Medicine and Biology, vol. 39, no. 6, pp. 785–794, 2012. View at Publisher · View at Google Scholar
  39. R. Haubner, S. Maschauer, J. Einsiedel et al., “H-CRRETAWAC-OH, a lead structure for the development of tracer targeting integrin α5β1?” BioMed Research International. In press.
  40. S. H. Hausner, C. K. Abbey, R. J. Bold et al., “Targeted in vivo imaging of integrin αvβ6 with an improved radiotracer and its relevance in a pancreatic tumor model,” Cancer Research, vol. 69, no. 14, pp. 5843–5850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. S. H. Hausner, R. D. Carpenter, N. Bauer, and J. L. Sutcliffe, “Evaluation of an integrin αvβ6-specific peptide labeled with [18F]fluorine by copper-free, strain-promoted click chemistry,” Nuclear Medicine and Biology, vol. 40, no. 2, pp. 233–239, 2013. View at Publisher · View at Google Scholar
  42. A. Saha, D. Ellison, G. J. Thomas et al., “High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin αvβ6,” The Journal of Pathology, vol. 222, no. 1, pp. 52–63, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Y. Hu, N. Bauer, L. M. Knight et al., “Characterization and evaluation of 64Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ6,” Molecular Imaging and Biology, 2014. View at Publisher · View at Google Scholar
  44. R. H. Kimura, R. Teed, B. J. Hackel et al., “Pharmacokinetically stabilized cystine knot peptides that bind αvβ6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer,” Clinical Cancer Research, vol. 18, no. 3, pp. 839–849, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. X. Zhu, J. Li, Y. Hong et al., “99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging,” Molecular Pharmaceutics, vol. 11, no. 4, pp. 1208–1217, 2014. View at Publisher · View at Google Scholar
  46. R. Haubner, H.-J. Wester, U. Reuning et al., “Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting,” The Journal of Nuclear Medicine, vol. 40, no. 6, pp. 1061–1071, 1999. View at Google Scholar · View at Scopus
  47. R. Haubner, H.-J. Wester, W. A. Weber et al., “Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography,” Cancer Research, vol. 61, no. 5, pp. 1781–1785, 2001. View at Google Scholar · View at Scopus
  48. A. J. Beer, R. Haubner, M. Goebel et al., “Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-Galacto-RGD in cancer patients,” The Journal of Nuclear Medicine, vol. 46, no. 8, pp. 1333–1341, 2005. View at Google Scholar · View at Scopus
  49. A. J. Beer, R. Haubner, M. Sarbia et al., “Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man,” Clinical Cancer Research, vol. 12, no. 13, pp. 3942–3949, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. A. J. Beer, R. Haubner, I. Wolf et al., “PET-based human dosimetry of 18F-Galacto-RGD, a new radiotracer for imaging αvβ3 expression,” The Journal of Nuclear Medicine, vol. 47, no. 5, pp. 763–769, 2006. View at Google Scholar · View at Scopus
  51. ICRP, “Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007,” Annals of the ICRP, vol. 38, no. 1-2, pp. 7–33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. A. J. Beer, A.-L. Grosu, J. Carlsen et al., “[18F]Galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 13, no. 22, pp. 6610–6616, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. O. Schnell, B. Krebs, J. Carlsen et al., “Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography,” Neuro-Oncology, vol. 11, no. 6, pp. 861–870, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. A. J. Beer, S. Lorenzen, S. Metz et al., “Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG,” The Journal of Nuclear Medicine, vol. 49, no. 1, pp. 22–29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Hoshiga, C. E. Alpers, L. L. Smith, C. M. Giachelli, and S. M. Schwartz, “αvβ3 integrin expression in normal and atherosclerotic artery,” Circulation Research, vol. 77, no. 6, pp. 1129–1135, 1995. View at Google Scholar · View at Scopus
  56. A. S. Antonov, F. D. Kolodgie, D. H. Munn, and R. G. Gerrity, “Regulation of macrophage foam cell formation by αvβ3 integrin: potential role in human atherosclerosis,” The American Journal of Pathology, vol. 165, no. 1, pp. 247–258, 2004. View at Google Scholar · View at Scopus
  57. A. J. Beer, J. Pelisek, P. Heider et al., “PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis,” JACC: Cardiovascular Imaging, vol. 7, no. 2, pp. 178–187, 2014. View at Google Scholar
  58. B. J. McParland, M. P. Miller, T. J. Spinks et al., “The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers,” The Journal of Nuclear Medicine, vol. 49, no. 10, pp. 1664–1667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. M. R. Battle, J. L. Goggi, L. Allen, J. Barnett, and M. S. Morrison, “Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αvβ3-integrin and αvβ5-integrin imaging agent,” The Journal of Nuclear Medicine, vol. 52, no. 3, pp. 424–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. H. C. Kolb, K. Chen, J. C. Walsh et al., “Synthesis and imaging of an 18F-labelled RGD peptide for detecting αvβ3 integrin expression,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 52, supplement 1, pp. S67–S73, 2009. View at Publisher · View at Google Scholar
  61. H. Kolb, J. Walsh, Q. Liang et al., “18F-RGD-K5: a cyclic triazole-bearing RGD peptide for imaging integrin αvβ3 expression in vivo,” The Journal of Nuclear Medicine, vol. 50, supplement 2, p. 329, 2009. View at Google Scholar
  62. M. Doss, H. C. Kolb, J. J. Zhang et al., “Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans,” The Journal of Nuclear Medicine, vol. 53, no. 5, pp. 787–795, 2012. View at Publisher · View at Google Scholar
  63. H. J. Cho, J. D. Lee, J. Y. Park et al., “First in human evaluation of a newly developed integrin binding PET tracer, 18F-RGD-K5 in patients with breast cancer: comparison with 18F-FDG uptake pattern and microvessel density,” The Journal of Nuclear Medicine, vol. 50, supplement 2, p. 1910, 2009. View at Google Scholar
  64. J. H. Kim, J. S. Lee, K. W. Kang et al., “Whole-body distribution and radiation dosimetry of 68Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging,” Cancer Biotherapy & Radiopharmaceuticals, vol. 27, no. 1, pp. 65–71, 2012. View at Publisher · View at Google Scholar
  65. S. Fanti, M. Farsad, and L. Mansi, PET-CT Beyond FDG: A Quick Guide to Image Interpretation, Springer, Berlin, Germany, 2010.
  66. W. J. McBride, R. M. Sharkey, H. Karacay et al., “A novel method of 18F radiolabeling for PET,” The Journal of Nuclear Medicine, vol. 50, no. 6, pp. 991–998, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Lang, W. Li, N. Guo et al., “Comparison study of [18F]FAl-NOTA-PRGD2, [18F] FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice,” Bioconjugate Chemistry, vol. 22, no. 12, pp. 2415–2422, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Decristoforo, “Gallium-68—a new opportunity for PET available from a long shelflife generator automation and applications,” Current Radiopharmaceuticals, vol. 5, no. 3, pp. 212–220, 2012. View at Publisher · View at Google Scholar
  69. E. T. Clarke and A. E. Martell, “Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles,” Inorganica Chimica Acta, vol. 190, no. 1, pp. 37–46, 1991. View at Google Scholar · View at Scopus
  70. R. A. Dumont, F. Deininger, R. Haubner, H. R. Maecke, W. A. Weber, and M. Fani, “Novel 64Cu- and 68Ga-labeled RGD conjugates show improved PET imaging of αvβ3 integrin expression and facile radiosynthesis,” The Journal of Nuclear Medicine, vol. 52, no. 8, pp. 1276–1284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. T. L. Mindt, H. Struthers, L. Brans et al., ““Click to chelate”: synthesis and installation of metal chelates into biomolecules in a single step,” Journal of the American Chemical Society, vol. 128, no. 47, pp. 15096–15097, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. V. D. Bock, H. Hiemstra, and J. H. van Maarseveen, “CuI-catalyzed alkyne-azide “click” cycloadditions from a mechanistic and synthetic perspective,” European Journal of Organic Chemistry, vol. 2006, no. 1, pp. 51–68, 2006. View at Google Scholar
  73. K. Kettenbach, H. Schieferstein, and T. Ross, “18F-labeling using click cycloadditions,” BioMed Research International. In press.
  74. S. Maschauer and O. Prante, “Sweetening pharmaceutical radiochemistry by 18F-fluoroglycosylation: a short review,” BioMed Research International. In press.
  75. S. Maschauer and O. Prante, “A series of 2-O-trifluoromethylsulfonyl-d-mannopyranosides as precursors for concomitant 18F-labeling and glycosylation by click chemistry,” Carbohydrate Research, vol. 344, no. 6, pp. 753–761, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Maschauer, J. Einsiedel, R. Haubner et al., “Labeling and glycosylate of peptides using click chemistry: a general approach to 18F-glycopeptides as effective imaging probes for positron emission tomography,” Angewandte Chemie, vol. 49, no. 5, pp. 976–979, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Liu, H. Liu, H. Jiang, Y. Xu, H. Zhang, and Z. Cheng, “One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 9, pp. 1732–1741, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. W. J. McBride, C. A. D'souza, R. M. Sharkey et al., “Improved 18F labeling of peptides with a fluoride-aluminum- chelate complex,” Bioconjugate Chemistry, vol. 21, no. 7, pp. 1331–1340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Guo, L. Lang, W. Li et al., “Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model,” PLoS ONE, vol. 7, no. 5, Article ID e37506, 2012. View at Publisher · View at Google Scholar
  80. N. Guo, L. Lang, H. Gao et al., “Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model,” Molecular Imaging and Biology, vol. 14, no. 6, pp. 743–752, 2012. View at Google Scholar
  81. D. Heckmann, A. Meyer, B. Laufer, G. Zahn, R. Stragies, and H. Kessler, “Rational design of highly active and selective ligands for the α5β1 integrin receptor,” ChemBioChem, vol. 9, no. 9, pp. 1397–1407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Koivunen, B. Wang, and E. Ruoslahti, “Isolation of a highly specific ligand for the α5β1 integrin from a phage display library,” The Journal of Cell Biology, vol. 124, no. 3, pp. 373–380, 1994. View at Google Scholar · View at Scopus
  83. D. Logan, R. Abu-Ghazaleh, W. Blakemore et al., “Structure of a major immunogenic site on foot-and-mouth disease virus,” Nature, vol. 362, no. 6420, pp. 566–568, 1993. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Jackson, D. Sheppard, M. Denyer, W. Blakemore, and A. M. Q. King, “The epithelial integrin αvβ6 is a receptor for foot-and-mouth disease virus,” Journal of Virology, vol. 74, no. 11, pp. 4949–4956, 2000. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Burman, S. Clark, N. G. A. Abrescia, E. E. Fry, D. I. Stuart, and T. Jackson, “Specificity of the VP1 GH loop of foot-and-mouth disease virus for αv integrins,” Journal of Virology, vol. 80, no. 19, pp. 9798–9810, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Kraft, B. Diefenbach, R. Mehta, A. Jonczyk, G. A. Luckenbach, and S. L. Goodman, “Definition of an unexpected ligand recognition motif for αvβ6 integrin,” The Journal of Biological Chemistry, vol. 274, no. 4, pp. 1979–1985, 1999. View at Publisher · View at Google Scholar · View at Scopus
  87. A. E. John, J. C. Luckett, A. L. Tatler et al., “Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis,” The Journal of Nuclear Medicine, vol. 54, no. 12, pp. 2146–2152, 2013. View at Publisher · View at Google Scholar